Pharming april 2018

7.620 Posts, Pagina: « 1 2 3 4 5 6 ... 322 323 324 325 326 327 328 329 330 331 332 ... 377 378 379 380 381 » | Laatste
lucas D
0
quote:

knaap1 schreef op 26 april 2018 12:50:


[...]


Soms jaren maar komt goed.


Ongeduld rendeert niet. Wacht gewoon eens af wat er werkelijk uit de 1e kwartaalcijfers komt, pas dan hebben we een richtlijn voor de rest van het jaar.

knaap1
0
quote:

lucas D schreef op 26 april 2018 12:57:


[...]

Ongeduld rendeert niet. Wacht gewoon eens af wat er werkelijk uit de 1e kwartaalcijfers komt, pas dan hebben we een richtlijn voor de rest van het jaar.




Lucas ik weet wat wachten is hoor vanaf 2013 zit ik in Pharming met soms wat verkoop en koop
BioBio
0
Immunology
Immunology product sales were $1,126 million in Q1 2018. Our immunoglobulin therapies and bio therapeutics each
reported growth of 12%. Immunoglobulin therapies growth was primarily driven by continued growth in subcutaneous
products, international markets, and increased demand in the U.S., partially offset by U.S. destocking compared to
the prior year. HAE product sales were up 1% with FIRAZYR growth offset by a decline in CINRYZE. FIRAZYR results
benefited from stocking during the current quarter compared to slight destocking in the prior year. FIRAZYR also
benefited from price increases and, to a lesser extent, higher demand. CINRYZE’s year-over-year decline resulted
from destocking in the quarter as well as an impact on demand from a competitor launch. Bio therapeutics growth was
driven by demand and favorable foreign currency exchange.
[verwijderd]
0
Press Release

SHIRELOGOA11.JPG

Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018

Growth driven by Immunology, recently-launched products, and international expansion

Innovative pipeline progresses with 15 programs in Phase 3 and 7 programs in registration including lanadelumab

Delivers Non GAAP diluted earnings per ADS of $3.86 , up 6% year-on-year; GAAP diluted earnings per ADS were $1.81 , up 47%

$1.0 billion in net operating cash flow enabled continued debt pay down


April 26, 2018 – Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG), the leading global biotech company focused on rare diseases, announces unaudited results for the three months ended March 31, 2018 .

Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented:

“Shire is off to a good start in 2018 delivering on our key priorities of commercial execution, pipeline progression, debt pay down , and portfolio optimization. We generated product sales growth of 7% in the first quarter reaching $3.6 billion with important contributions from our Immunology franchise, recently-launched products, and international markets. We delivered $1.0 billion in net operating cash flow allowing us to remain on track towards our debt pay down target.

“We continue to advance our innovative pipeline with seven programs in registration including lanadelumab, the first monoclonal antibody being evaluated to prevent hereditary angioedema attacks, with the potential to change the treatment paradigm for this serious and sometimes life threatening rare disease.

“As part of the ongoing review of our portfolio, we recently announced an agreement for the sale of our Oncology franchise for $2.4 billion allowing us to unlock embedded value and sharpen our focus."


Product and Pipeline Highlights
Regulatory updates



Advanced lanadelumab with accelerated approval pathways underway in the U.S. (PDUFA date of August 26, 2018), Europe, and Canada.



Gained FDA acceptance for additional key filings: CINRYZE sBLA for pediatric use, including Priority Review; prucalopride NDA; and Calaspargase Pegol BLA.



Achieved marketing approval of XIIDRA (lifitegrast ophthalmic solution 5%) in Canada and ADYNOVI in E.U.



Obtained Breakthrough Therapy Designation for maribavir for cytomegalovirus (CMV) infection in transplant patients from FDA.

Clinical and business development updates



Agreed to divest Oncology franchise to Servier S.A.S. for $2.4 billion.



Formed pre-clinical research collaboration to evaluate a potential enzyme replacement therapy using NanoMedSyn’s proprietary synthetic derivatives.

Note: Growth rates are on a reported basis unless mentioned otherwise.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Financial Highlights



Q1 2018

Reported Growth

Non GAAP CER (1)
Product sales Rare Disease (2)

$2,719 million

+10%

+6%
Product sales Neuroscience (2)

$918 million

-2%

-4%
Total product sales

$3,637 million

+7%

+3%
Total revenues

$3,766 million

+5%

+2%


Rare Disease contribution margin (2)

$1,367 million

+2%

•Rare Disease reported contribution margin of $1,367 million , or 48% , and Neuroscience reported contribution margin of $770 million , or 82% .
[verwijderd]
0
FINANCIAL SUMMARY - FIRST QUARTER 2018 COMPARED TO FIRST QUARTER 2017

Revenues

•Delivered total revenues of $3,766 million representing growth of 5% .


Rare Disease product sales increased 10% to $2,719 million ( Q1 2017 : $2,472 million ), with growth across all franchises on a reported basis and growth from recently launched products. Rare Disease product sales also benefited from favorable foreign currency exchange in our international markets.
.

Operating results



Rare Disease contribution margin percentage was approximately 48% (Q1 2017: 51%), a slight decline from the prior year due to lower gross margins on sales, partially offset by lower selling and marketing costs.


SHIRELOGOA11.JPG
3

OUTLOOK

Our 2018 guidance, which continues to include our Oncology franchise, remains unchanged. It will be updated to remove the Oncology franchise upon the close of this pending sale later this year. Similarly, our 2020 guidance remains unchanged and will be updated to remove the Oncology franchise upon the close of this pending sale later this year.

The Non GAAP diluted earnings per ADS forecast assumes a weighted average number of 915 million fully diluted ordinary shares outstanding for 2018.

Our U.S. GAAP diluted earnings per ADS outlook reflects anticipated amortization, integration, and reorganization costs.

Risks associated with this outlook include the potential uncertainty resulting from the announcement by Takeda Pharmaceutical Company Limited that it is considering making a possible offer for Shire.

A3aan
0
Mag dat zo maar een plaatsing dat RABO 5,00 aangeeft. Geloof ik 10 jaar oud. Zo'n persoon hoort aangeklaagd te worden. Is dat mogelijk. Er zijn altijd nieuwe beleggers die er in tuinen.
[verwijderd]
0
Shire: Product sales Rare Disease +10%
Da's toch redelijk wat.

Volledige cijfers in bijlage
[verwijderd]
0

Amortization of acquired intangible assets

In Q1 2018 , Shire recorded amortization of acquired intangible assets of $484 million ( Q1 2017 : $364 million ), primarily related to the acceleration of CINRYZE amortization with the expected launch of SHP643, subject to regulatory approval.
eric de stier
0
quote:

KarenT schreef op 26 april 2018 13:22:


Shire: Product sales Rare Disease +10%
Da's toch redelijk wat.

Volledige cijfers in bijlage


Alle rare Disease is niet HEREDITARY ANGIOEDEMA

HEREDITARY ANGIOEDEMA(CYNR-FIRA-KALB) = 368.8 vs 366,1 in Q-17 bijna geen groei
beurschecker
0
quote:

KarenT schreef op 26 april 2018 13:22:


Shire: Product sales Rare Disease +10%
Da's toch redelijk wat.

Volledige cijfers in bijlage


1% als ik het goed lees. Cinryze omlaag, Firazyr omhoog.

HAE product sales were up 1% with FIRAZYR growth offset by a decline in CINRYZE. FIRAZYR results
beurschecker
1
CINRYZE’s year-over-year decline resulted
from destocking in the quarter as well as an impact on demand from a competitor launch.

8-)
NEVDK
0
Afschrijvingen op verworven immateriële activa

In Q1 2018 registreerde Shire de afschrijving van verworven immateriële activa van $ 484 miljoen (Q1 2017: $ 364 miljoen), voornamelijk in verband met de versnelling van CINRYZE-afschrijving met de verwachte lancering van SHP643, onder voorbehoud van goedkeuring door de toezichthouder.
Frank S.
0
quote:

Pharmlong schreef op 26 april 2018 13:12:


Immunology
Immunology product sales were $1,126 million in Q1 2018. Our immunoglobulin therapies and bio therapeutics each
reported growth of 12%. Immunoglobulin therapies growth was primarily driven by continued growth in subcutaneous
products, international markets, and increased demand in the U.S., partially offset by U.S. destocking compared to
the prior year. HAE product sales were up 1% with FIRAZYR growth offset by a decline in CINRYZE. FIRAZYR results
benefited from stocking during the current quarter compared to slight destocking in the prior year. FIRAZYR also
benefited from price increases and, to a lesser extent, higher demand. CINRYZE’s year-over-year decline resulted
from destocking in the quarter as well as an impact on demand from a competitor launch.
Bio therapeutics growth was
driven by demand and favorable foreign currency exchange.


De jaar-op-jaar daling van CINRYZE resulteerde
van voorraadafbouw in het kwartaal, evenals een impact op de vraag van de lancering van een concurrent.
NEVDK
0
De jaar-op-jaar daling van CINRYZE resulteerde
van voorraadafbouw in het kwartaal, evenals een impact op de vraag van de lancering van een concurrent.
De Zwarte Kat
0
quote:

A3aantje schreef op 26 april 2018 13:20:


Mag dat zo maar een plaatsing dat RABO 5,00 aangeeft. Geloof ik 10 jaar oud. Zo'n persoon hoort aangeklaagd te worden. Is dat mogelijk. Er zijn altijd nieuwe beleggers die er in tuinen.
Ben het nnet je eens dit kan echt niet zou eens contact op nennen nnet iex onn te beginnen
beurschecker
0
quote:

A & A schreef op 26 april 2018 13:41:


[...]Ben het nnet je eens dit kan echt niet zou eens contact op nennen nnet iex onn te beginnen


Lolll, is de M button kapot?
7.620 Posts, Pagina: « 1 2 3 4 5 6 ... 322 323 324 325 326 327 328 329 330 331 332 ... 377 378 379 380 381 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 18 jan 2021 17:37
Koers 1,222
Verschil +0,028 (+2,35%)
Hoog 1,225
Laag 1,181
Volume 5.410.533
Volume gemiddeld 11.874.214
Volume gisteren 6.870.193

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront